Biohaven Ltd. (BHVN)
NYSE:BHVN
Want to see BHVN full AI Analyst Report?
BHVN Stock Chart & Stats
$10.98
-$0.59(-1.49%)
At close: 4:00 PM EST
$10.98
-$0.59(-1.49%)
Day’s Range― - ―
52-Week Range$7.48 - $18.57
Previous CloseN/A
Volume146.24K
Average Volume (3M)2.23M
Market Cap
$1.72B
Enterprise Value$1.17B
Total Cash (Recent Filing)$347.82M
Total Debt (Recent Filing)$280.27M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Aug 03, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.67
Shares Outstanding150,560,990
10 Day Avg. Volume2,939,067
30 Day Avg. Volume2,227,466
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)23.33
Price to Sales (P/S)0.00
P/FCF Ratio-1.99
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-567.93
Enterprise Value/Ebitda-1.80
Forecast
1Y Price Target
$18.64Price Target Upside69.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Progress — OpakalimRobust proof-of-concept efficacy and differentiated tolerability materially strengthen Biohaven’s CNS pipeline. Progress toward pivotal Phase 2/3 readouts in 2H 2026 creates a durable program-level catalyst that can translate into regulatory pathways, commercial opportunities, and partnership interest if replicated in larger trials.
Governance ContinuityStrong shareholder backing and stable board/audit oversight reduce governance risk during critical development milestones. Continuity in leadership supports consistent strategic execution across pivotal trials and financing decisions, improving institutional confidence for multi-quarter operational plans and partner negotiations.
Equity Financing FlexibilityAn expanded at-the-market facility provides durable access to incremental capital over time, smoothing funding of clinical programs and operations. This structural financing optionality lowers the need for one-off dilutive transactions and supports multi-quarter runway management, aiding continued R&D execution.
Bears Say
Zero Revenue / Large LossesPersistent zero reported revenue and very large net losses reflect that Biohaven has not yet converted clinical progress into commercial cash flows. This structural earnings gap forces reliance on external funding and makes long-term viability contingent on successful late-stage results or product commercialization.
Deteriorated Balance SheetA sharp jump in leverage and collapsing equity materially increases financial fragility. Elevated debt-to-equity ratios reduce strategic flexibility, raise financing costs, and amplify downside from trial delays or regulatory setbacks, making the company more dependent on capital markets and partner transactions.
Heavy Cash Burn / Negative FCFSustained negative operating and free cash flow creates continual funding requirements and heightens dilution risk. Ongoing burn constrains ability to scale programs or invest opportunistically, making multi-quarter program timelines and go-to-market planning contingent on timely capital access or material revenue generation.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $18.57 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $1.72B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Aug 03, 2026 which is in 58 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on May 04, 2026. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.831 by -$0.049.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -0.74.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 150,560,990 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.831. Following the earnings report the stock price went down -4.241%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.64 (69.73% Upside)
$18.64 (69.73% Upside)
Blogger Sentiment
Neutral
BHVN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 757.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.67%
12-Months-Change
Fundamentals
Return on Equity
-866.46%
Trailing 12-Months
Asset Growth
1.63%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
BHVN Stock 12 Month Forecast
Average Price Target
$18.64
▲(69.73% Upside)
Technical Analysis
Ownership Overview
10.77% Insiders
11.54% Mutual Funds
33.60% Other Institutional Investors
33.93% Public Companies and
Individual Investors